A dual-armed oncolytic virus shows clinical efficacy in advanced solid cancers.

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

An oncolytic adenovirus armed with tumor necrosis factor-α and interleukin-2 was tested in patients with advanced solid tumors. Antitumor effects were observed in both treated and non-treated lesions, leading to long-term survival in some patients. This clinical trial shows the potential of oncolytic virotherapy for patients refractory to standard therapies.

Keyphrases

end stage renal disease
newly diagnosed
clinical trial
ejection fraction
chronic kidney disease
prognostic factors
rheumatoid arthritis
randomized controlled trial
study protocol
patient reported
double blind
phase ii